A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor (SERENA-6) Principal Investigator:
Clinical Trial Type: Breast
SGN B7H4V-001 (Seagen, Inc.)
Description: A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors Target Patient Population: Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers. Study Design: Drug is administered IV 21 day cycle (Day 1, 8 or Day 1 only)
TH1902-CTR-0001 (Theratechnologies, Inc.)
Description: A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer Target Patient Population: Currently in Dose Escalation with all Solid Tumors. Study Design: Drug is administered IV every 3 weeks.